94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1607882
Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC
Provisionally accepted
Julia Meidenbauer1,2,3
Matthias Wachter1,2,3Sebastian R Schulz4
Nada Mostafa1,2,3
Lilli Zülch1,2,3
Benjamin Frey1,2,3,5,6
Rainer Fietkau2,3,5,6
Udo S Gaipl1,2,3,5,6
Tina Jost1,2,3*- 1Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
- 2Uniklinikum Erlangen Department of Radiation Oncology, Erlangen, Bavaria, Germany
- 3Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg (EMN), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 4Division of Molecular Immunology, Internal Medicine III, University Hospital Erlangen, Nikolaus-Fiebiger Center, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
- 5Deutsches Zentrum Immuntherapie, Uniklinikum Erlangen, Erlangen, Germany
- 6FAU Profile Center Immunomedicine Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
FUNDINGThe author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the DFG Doctoral Training Group 2599 “Fine-Tuners of the Adaptive Immune Response” and partly by the Interdisciplinary Center for Clinical Research (IZKF) in Erlangen. The present work was performed by Julia Meidenbauer in (partial) fulfilment of the requirements for obtaining the degree “Dr. med.” at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).
Keywords: HNSCC, DNA damage repair, kinase inhibitors, Immunomodulation, ATM inhibition, ATR inhibition
Received: 08 Apr 2025; Accepted: 09 Apr 2025.
Copyright: © 2025 Meidenbauer, Wachter, Schulz, Mostafa, Zülch, Frey, Fietkau, Gaipl and Jost. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tina Jost, Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.